今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ 8-K Current report, items 1.01, 5.03, 5.07, and 9.01 Accession Number: 0001213900-21-029632 Act: 34 Size: 334 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-21-028363 Act: 34 Size: 293 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001213900-21-028222 Act: 34 Size: 278 KB 网页链接
$Trident(TDAC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-21-028223 Act: 34 Size: 88 KB 网页链接
$Trident(TDAC)$ NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB Accession Number: 0001213900-21-027135 Act: 34 Size: 28 KB 网页链接
$Trident(TDAC)$ DEF 14A Other definitive proxy statements Accession Number: 0001213900-21-026583 Act: 34 Size: 149 KB 网页链接
$Trident(TDAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001213900-21-025678 Size: 5 KB 网页链接
$Trident(TDAC)$ PRE 14A Other preliminary proxy statements Accession Number: 0001213900-21-024720 Act: 34 Size: 146 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-023371 Act: 34 Size: 48 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-023369 Act: 34 Size: 29 KB 网页链接